12 Month Price Forecast For TFX
Distance to TFX Price Forecasts
TFX Price Momentum
๐ค Considering Teleflex (TFX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 5, 2025 5:21 PM UTC
TFX Analyst Ratings & Price Targets
Based on our analysis of 24 Wall Street analysts, TFX has a consensus that is neutral. The median price target is $230.00, with forecasts ranging from $200.00 to $285.00. Currently, there are 5 Buy ratings, 9 Hold ratings, and 0 Sell ratings.
With TFX currently trading at $174.90, the median price forecast suggests a 31.5% upside. The most optimistic forecast comes from David Turkaly at JMP Securities, projecting a 63.0% upside, while Richard Newitter at Truist Securities provides the most conservative target, suggesting a 14.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TFX Analyst Consensus
TFX Price Target Range
Latest TFX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TFX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 18, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $200.00 |
Dec 16, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
Nov 4, 2024 | Truist Securities | Richard Newitter | Hold | Reiterates | $227.00 |
Nov 1, 2024 | Mizuho | Anthony Petrone | Neutral | Maintains | $250.00 |
Nov 1, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $245.00 |
Nov 1, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
Oct 14, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $255.00 |
Oct 8, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $275.00 |
Aug 6, 2024 | RBC Capital | Shagun Singh | Outperform | Reiterates | $260.00 |
Aug 5, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $247.00 |
Aug 2, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $260.00 |
Aug 2, 2024 | Stephens & Co. | George Sellers | Overweight | Maintains | $290.00 |
Jul 16, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $240.00 |
Jul 9, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $235.00 |
Jul 1, 2024 | Piper Sandler | Matt O'Brien | Overweight | Upgrade | $245.00 |
May 3, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
May 3, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $219.00 |
Feb 23, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $265.00 |
Feb 23, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $265.00 |
Feb 23, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $285.00 |
Stocks Similar to Teleflex Inc
The following stocks are similar to Teleflex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Teleflex Inc (TFX) Financial Data
Teleflex Inc has a market capitalization of $8.12B with a P/E ratio of 34.7x. The company generates $3.03B in trailing twelve-month revenue with a 7.8% profit margin.
Revenue growth is +2.4% quarter-over-quarter, while maintaining an operating margin of +19.6% and return on equity of +5.4%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Teleflex Inc (TFX) Company Overview
About Teleflex Inc
Develops single-use medical devices for healthcare.
The company generates revenue by designing, manufacturing, and supplying a range of single-use medical devices that are critical for diagnostic and therapeutic procedures. Its diverse product portfolio includes vascular access products, anesthesia devices, surgical instruments, and interventional urology products, catering to hospitals, healthcare providers, and home care markets worldwide.
Founded in 1943 and based in Wayne, Pennsylvania, the company has a strong focus on critical care and surgical applications, positioning itself to meet the needs of interventional cardiologists, radiologists, and various medical professionals. Its established brand recognition and wide array of products cater to both hospital settings and home care, providing growth opportunities in multiple healthcare sectors.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
14,500
CEO
Mr. Liam J. Kelly
Country
United States
IPO Year
1988
Website
www.teleflex.comTeleflex Inc (TFX) Latest News & Analysis
Teleflex Incorporated has secured a contract with Vizient, effective January 1, 2025, to supply Central Venous Access and Arterial Catheters, enhancing its market position in medical technologies.
A contract with Vizient enhances Teleflex's market position and revenue potential, reflecting strong demand for its medical technologies among a significant portion of U.S. healthcare providers.
Glancy Prongay & Murray LLP is investigating Teleflex Incorporated (NYSE: TFX) for possible violations of state laws by the company and its executives.
The investigation into Teleflex's potential legal violations could lead to financial liabilities, affecting stock performance and investor confidence.
Liam Kelly, CEO of Teleflex Incorporated (NYSE: TFX), will speak at the J.P. Morgan Healthcare Conference on January 14, 2025, at 5:15 p.m. PT in San Francisco.
Liam Kelly's upcoming speech at a prominent healthcare conference may provide insights into Teleflex's strategy and performance, influencing investor sentiment and stock movement.
TFX remains notable for investors due to strong performance in the Vascular Access segment and ongoing expansion initiatives.
TFX's strong performance in the Vascular Access segment and expansion efforts signal growth potential, which can enhance shareholder value and attract investment interest.
Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their investment portfolios.
The Zacks Style Scores can help investors identify high-potential stocks, potentially leading to better portfolio performance and enhanced returns.
Teleflex has launched the Arrowg+ard Blue Plus MSB Procedure Kit in the EMEA region.
Teleflex's launch of the Arrowg+ard Blue Plus MSB Procedure Kit in EMEA could boost sales and market share, indicating growth potential and innovation, which may positively impact stock performance.
Frequently Asked Questions About TFX Stock
What is Teleflex Inc's (TFX) stock forecast for 2025?
Based on our analysis of 24 Wall Street analysts, Teleflex Inc (TFX) has a median price target of $230.00. The highest price target is $285.00 and the lowest is $200.00.
Is TFX stock a good investment in 2025?
According to current analyst ratings, TFX has 5 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $174.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for TFX stock?
Wall Street analysts predict TFX stock could reach $230.00 in the next 12 months. This represents a 31.5% increase from the current price of $174.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Teleflex Inc's business model?
The company generates revenue by designing, manufacturing, and supplying a range of single-use medical devices that are critical for diagnostic and therapeutic procedures. Its diverse product portfolio includes vascular access products, anesthesia devices, surgical instruments, and interventional urology products, catering to hospitals, healthcare providers, and home care markets worldwide.
What is the highest forecasted price for TFX Teleflex Inc?
The highest price target for TFX is $285.00 from David Turkaly at JMP Securities, which represents a 63.0% increase from the current price of $174.90.
What is the lowest forecasted price for TFX Teleflex Inc?
The lowest price target for TFX is $200.00 from Richard Newitter at Truist Securities, which represents a 14.4% increase from the current price of $174.90.
What is the overall TFX consensus from analysts for Teleflex Inc?
The overall analyst consensus for TFX is neutral. Out of 24 Wall Street analysts, 5 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $230.00.
How accurate are TFX stock price projections?
Stock price projections, including those for Teleflex Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.